Marathon Wealth Advisors LLC Buys New Stake in Zoetis Inc. $ZTS

Marathon Wealth Advisors LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,057 shares of the company’s stock, valued at approximately $842,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at $28,000. Wellington Grp LLC boosted its holdings in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares in the last quarter. Global Assets Advisory LLC bought a new stake in Zoetis in the first quarter worth $38,000. University of Texas Texas AM Investment Management Co. bought a new stake in Zoetis in the second quarter worth $25,000. Finally, Dunhill Financial LLC increased its position in Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.2%

Shares of ZTS stock opened at $82.48 on Wednesday. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $132.49. The firm has a market cap of $33.51 billion, a PE ratio of 14.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.67. The stock has a 50 day moving average of $75.88 and a 200-day moving average of $92.18. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.24. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. Zoetis’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.70 earnings per share. On average, equities analysts predict that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is presently 36.05%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. BTIG Research dropped coverage on Zoetis in a report on Friday, October 30th. They set a “buy” rating and a $200.00 target price on the stock. Piper Sandler decreased their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. BNP Paribas Exane decreased their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. William Blair lowered Zoetis from an “outperform” rating to a “market perform” rating in a report on Thursday, August 6th. Finally, Zacks Research raised Zoetis from a “strong sell” rating to a “hold” rating in a research note on Monday, October 26th. Eight equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $101.25.

Zoetis Company Profile

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.